MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named ...
MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a significant advancement for ...
MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the ...
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, announced innovations to its Revio and Vega platforms last week. The innovations are expected to lower sequencing costs, add ...
MENLO PARK, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it has joined the 1000 Genomes ...
PacBio's Advanced Sequencing Solutions Enable Breakthrough in Understanding Rare Mendelian Condition
PacBio announced its involvement in a groundbreaking study published in Nature Genetics, which utilized its advanced sequencing technology to explore the genetic basis of a rare Mendelian condition in ...
Pacific Biosciences of California, Inc. is downgraded to Hold with slow commercial adoption & academic funding pressures.
PacBio announced the early shipment of its Vega benchtop sequencing system and the launch of SPRQ chemistry, enabling affordable HiFi genome sequencing for under $500 on the Revio system. Despite ...
Pacific Biosciences of California, Inc. PACB and Intus Bio, a leader in microbiome research and discovery, recently unveiled GutID, the first commercial human gut health test powered by Intus Bio’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback